Get started
Author

Tereza Lanitis

Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature
2014 · Kevin Marsh, Tereza Lanitis, et al. · PharmacoEconomics · 278
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
2014 · P. Dorian, T. Kongnakorn, et al. · European Heart Journal · 98
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
2014 · Gregory Y.H. Lip, Thitima Kongnakorn, et al. · Clinical Therapeutics · 87
PDF
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin
2014 · T. Lanitis, F. E. Cotté, et al. · Journal of Medical Economics · 72
PDF
Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
2018 · Luis Hernandez, Tereza Lanitis, et al. · Journal of Managed Care & Specialty Pharmacy · 34
PDF
Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the United States in 2020
2020 · Andrew A. Moshfeghi, Tereza Lanitis, et al. · Ophthalmic surgery, lasers & imaging retina · 32
Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
2014 · Tereza Lanitis, Thitima Kongnakorn, et al. · Thrombosis Research · 30
PDF
Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin
2014 · Thitima Kongnakorn, Tereza Lanitis, et al. · Clinical Drug Investigation · 26
Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA
2019 · Mustafa Oguz, Tereza Lanitis, et al. · Applied Health Economics and Health Policy · 23
PDF
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence
2016 · Tereza Lanitis, Robert Leipold, et al. · Clinical Therapeutics · 23
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
2019 · Tereza Lanitis, Irina Proskorovsky, et al. · Advances in Therapy · 16
PDF
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
2017 · Tereza Lanitis, Robert Leipold, et al. · BMC Health Services Research · 16
PDF
Incorporating Preferences and Priorities into MCDA: Selecting an Appropriate Scoring and Weighting Technique
2017 · Kevin Marsh, Praveen Thokala, et al. · Springer eBooks · 16
Cost Effectiveness of Apixaban Versus Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in Belgium
2014 · Thitima Kongnakorn, Tereza Lanitis, et al. · Clinical Drug Investigation · 16
The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland
2015 · VAH Coles, R Chapman, et al. · International Journal of STD & AIDS · 13
The cost of managing genital warts in the UK
2012 · T Lanitis, S Carroll, et al. · International Journal of STD & AIDS · 13
The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma
2016 · Noemi Muszbek, Ananth Kadambi, et al. · Clinical Therapeutics · 11
PDF
Cost-effectiveness of atrial fibrillation screening in Canadian community practice
2022 · Jason G. Andrade, Anshul Shah, et al. · Heart Rhythm O2 · 10
PDF
Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
2015 · Gregory Y.H. Lip, Tereza Lanitis, et al. · Clinical Therapeutics · 9
PDF
Simulated Treatment Comparison of Time-To-Event (And Other Non-Linear) Outcomes
2015 · KJ Ishak, M Rael, et al. · Value in Health · 7
PDF
Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation
2019 · Amber L Martin, Alessandra G Reeves, et al. · Journal of Comparative Effectiveness Research · 6
Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients
2015 · Gregory Y.H. Lip, Tereza Lanitis, et al. · Stroke · 6
Value Assessment of Immuno-Oncology in the Treatment of Rare Tumors in the Era of Accelerated Conditional Approvals
2019 · Tereza Lanitis, Apoorva Ambavane, et al. · Future Oncology · 5
Cost-Effectiveness Of Apixaban Compared To Other Anticoagulants For Lifetime Treatment And Prevention Of Recurrent Venous Thromboembolism
2014 · T. Lanitis, M. Hamilton, et al. · Value in Health · 5
Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism
2016 · C. Browne, T. Lanitis, et al. · Journal of Medical Economics · 3
PDF
Works count: 52
Citation count: 867
H-index: 14
I10-index: 18
Year
Topic
Type